PRAX Fundamental Analysis - PRAXIS PRECISION MEDICINES I

Name: PRAXIS PRECISION MEDICINES I (PRAX) Stock
Brand: PRAXIS PRECISION MEDICINES I
Rating: 6.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to PRAX. PRAX was compared to 534 industry peers in the Biotechnology industry. While PRAX has a great health rating, there are worries on its profitability. PRAX is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PRAX has reported negative net income.

In the past year PRAX has reported a negative cash flow from operations.

In the past 5 years PRAX always reported negative net income.

In the past 5 years PRAX always reported negative operating cash flow.

1.2 Ratios

PRAX has a Return On Assets (-55.43%) which is comparable to the rest of the industry.

PRAX's Return On Equity of -62.10% is fine compared to the rest of the industry. PRAX outperforms 60.86% of its industry peers.

		Industry Rank	Sector Rank
ROA	-55.43%
ROE	-62.1%
ROIC	N/A

ROA(3y)-121.32%

ROA(5y)-88.85%

ROE(3y)-166.41%

ROE(5y)-118.06%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PRAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, PRAX has more shares outstanding

PRAX has less shares outstanding than it did 5 years ago.

There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PRAX has an Altman-Z score of 47.64. This indicates that PRAX is financially healthy and has little risk of bankruptcy at the moment.

PRAX has a Altman-Z score of 47.64. This is amongst the best in the industry. PRAX outperforms 96.44% of its industry peers.

There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	47.64

ROIC/WACCN/A

WACC8.75%

2.3 Liquidity

PRAX has a Current Ratio of 6.31. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.

PRAX's Current ratio of 6.31 is fine compared to the rest of the industry. PRAX outperforms 65.73% of its industry peers.

PRAX has a Quick Ratio of 6.31. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 6.31, PRAX is in the better half of the industry, outperforming 66.10% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.31
Quick Ratio	6.31

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PRAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.90%.

Looking at the last year, PRAX shows a very strong growth in Revenue. The Revenue has grown by 338.45%.

EPS 1Y (TTM)-19.9%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-90.23%

Revenue 1Y (TTM)338.45%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

PRAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.92% yearly.

Based on estimates for the next years, PRAX will show a very strong growth in Revenue. The Revenue will grow by 209.56% on average per year.

EPS Next Y-33.71%

EPS Next 2Y-12.61%

EPS Next 3Y2.09%

EPS Next 5Y15.92%

Revenue Next Year-93.69%

Revenue Next 2Y-71.01%

Revenue Next 3Y348.5%

Revenue Next 5Y209.56%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRAX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRAX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-12.61%

EPS Next 3Y2.09%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PRAX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PRAXIS PRECISION MEDICINES I

NASDAQ:PRAX (11/3/2025, 8:24:10 PM)

After market: 180 -1.99 (-1.09%)

181.99

-16.77 (-8.44%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-04 2025-08-04/bmo

Earnings (Next)11-04 2025-11-04/bmo

Inst Owners107.23%

Inst Owner Change-0.59%

Ins Owners0.19%

Ins Owner Change0.4%

Market Cap3.85B

Revenue(TTM)7.76M

Net Income(TTM)-251012000

Analysts82

Price Target258.64 (42.12%)

Short Float %13.22%

Short Ratio3.22

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)0.9%

Min EPS beat(2)-0.77%

Max EPS beat(2)2.57%

EPS beat(4)1

Avg EPS beat(4)-8.75%

Min EPS beat(4)-35.55%

Max EPS beat(4)2.57%

EPS beat(8)4

Avg EPS beat(8)1.98%

EPS beat(12)6

Avg EPS beat(12)3.25%

EPS beat(16)7

Avg EPS beat(16)0.2%

Revenue beat(2)0

Avg Revenue beat(2)-100%

Min Revenue beat(2)-100%

Max Revenue beat(2)-100%

Revenue beat(4)2

Avg Revenue beat(4)434.4%

Min Revenue beat(4)-100%

Max Revenue beat(4)1937.56%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)151.06%

PT rev (3m)155.7%

EPS NQ rev (1m)-0.08%

EPS NQ rev (3m)-5.76%

EPS NY rev (1m)-0.72%

EPS NY rev (3m)-3.73%

Revenue NQ rev (1m)-7.7%

Revenue NQ rev (3m)-71.8%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-78.55%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	496.17
P/FCF	N/A
P/OCF	N/A
P/B	9.53
P/tB	9.53
EV/EBITDA	N/A

EPS(TTM)-12.29

EYN/A

EPS(NY)-13.02

Fwd EYN/A

FCF(TTM)-9.04

FCFYN/A

OCF(TTM)-9.04

OCFYN/A

SpS0.37

BVpS19.09

TBVpS19.09

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-55.43%
ROE	-62.1%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-121.32%

ROA(5y)-88.85%

ROE(3y)-166.41%

ROE(5y)-118.06%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.31
Quick Ratio	6.31
Altman-Z	47.64

F-Score4

WACC8.75%

ROIC/WACCN/A

Cap/Depr(3y)38.78%

Cap/Depr(5y)139.93%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-19.9%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-90.23%

EPS Next Y-33.71%

EPS Next 2Y-12.61%

EPS Next 3Y2.09%

EPS Next 5Y15.92%

Revenue 1Y (TTM)338.45%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

Revenue Next Year-93.69%

Revenue Next 2Y-71.01%

Revenue Next 3Y348.5%

Revenue Next 5Y209.56%

EBIT growth 1Y-104.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-51.21%

EBIT Next 3Y-12.13%

EBIT Next 5Y-0.66%

FCF growth 1Y-38.84%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-38.85%

OCF growth 3YN/A

OCF growth 5YN/A

PRAXIS PRECISION MEDICINES I / PRAX FAQ

What is the ChartMill fundamental rating of PRAXIS PRECISION MEDICINES I (PRAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRAX.

Can you provide the valuation status for PRAXIS PRECISION MEDICINES I?

ChartMill assigns a valuation rating of 0 / 10 to PRAXIS PRECISION MEDICINES I (PRAX). This can be considered as Overvalued.

What is the profitability of PRAX stock?

PRAXIS PRECISION MEDICINES I (PRAX) has a profitability rating of 1 / 10.

What is the expected EPS growth for PRAXIS PRECISION MEDICINES I (PRAX) stock?

The Earnings per Share (EPS) of PRAXIS PRECISION MEDICINES I (PRAX) is expected to decline by -33.71% in the next year.

PRAXIS PRECISION MEDICINES I (PRAX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

PRAXIS PRECISION MEDICINES I / PRAX FAQ

What is the ChartMill fundamental rating of PRAXIS PRECISION MEDICINES I (PRAX) stock?

Can you provide the valuation status for PRAXIS PRECISION MEDICINES I?

What is the profitability of PRAX stock?

What is the expected EPS growth for PRAXIS PRECISION MEDICINES I (PRAX) stock?